1. Non-catecholamine adrenergic agonists differ from catecholamines in a structural feature that has direct pharmacokinetic consequences. Which of the following correctly identifies this structural distinction and its most important clinical consequence?

• A) Non-catecholamines differ from catecholamines by having a fluorine atom substituted at the 4-position of the benzene ring; fluorine substitution prevents COMT binding and confers resistance to oxidative metabolism, explaining the longer duration of action of all non-catecholamine adrenergic agonists
• B) Non-catecholamines differ from catecholamines by having an additional methyl group on the alpha-carbon of the amine side chain; this alpha-methyl group blocks MAO access at the amine and is the sole structural feature responsible for oral bioavailability of all non-catecholamines
• C) Non-catecholamines lack the catechol ring — the 3,4-dihydroxybenzene structure — that catecholamines possess; because COMT requires this catechol ring to methylate its substrate, non-catecholamines are not COMT substrates; many are also poor MAO substrates due to additional structural modifications; the primary clinical consequence is longer duration of action and oral bioavailability for many agents in this class
• D) Non-catecholamines differ from catecholamines only in their route of administration — catecholamines must be given intravenously while non-catecholamines are exclusively oral agents; the structural distinction is pharmacologically irrelevant because both classes are metabolized by the same hepatic CYP450 enzymes
• E) Non-catecholamines differ from catecholamines by lacking the amine side chain entirely; without an amine group, non-catecholamines cannot be metabolized by MAO and therefore persist indefinitely in the body; their duration of action is limited only by renal excretion

2. Phenylephrine is one of the most widely used non-catecholamine adrenergic agonists, appearing in both over-the-counter nasal decongestants and as an intravenous vasopressor in clinical settings. Which of the following correctly identifies phenylephrine's receptor selectivity and its primary hemodynamic effect?

• A) Phenylephrine is a non-selective adrenergic agonist with activity at alpha-1, alpha-2, beta-1, and beta-2 receptors; it produces a mixed hemodynamic profile including vasoconstriction, bronchodilation, and cardiac stimulation simultaneously, making it functionally similar to epinephrine but with longer duration of action
• B) Phenylephrine is a selective beta-2 adrenergic agonist used primarily as a bronchodilator; its nasal decongestant effect results from beta-2-mediated vasodilation in nasal mucosal vessels that reduces mucosal engorgement; it is structurally related to albuterol and salbutamol
• C) Phenylephrine is a selective alpha-2 adrenergic agonist that reduces sympathetic outflow by activating central presynaptic autoreceptors; it lowers blood pressure rather than raising it, and is classified alongside clonidine and dexmedetomidine as a centrally acting antihypertensive
• D) Phenylephrine is a selective alpha-1 adrenergic agonist with no clinically significant beta receptor activity; alpha-1 activation on vascular smooth muscle produces vasoconstriction, increasing systemic vascular resistance and raising mean arterial pressure; the resulting blood pressure rise activates baroreceptors, producing reflex bradycardia; nasal decongestant effect results from alpha-1-mediated constriction of nasal mucosal blood vessels, reducing engorgement and improving airflow
• E) Phenylephrine is a selective alpha-1 adrenergic agonist with no clinically significant beta receptor activity; its dominant effect is vasoconstriction through Gq/PLC/IP3/calcium-mediated smooth muscle contraction; the blood pressure rise it produces triggers baroreceptor-mediated reflex bradycardia; it is distinguished from norepinephrine by its lack of beta-1 activity, meaning it does not directly increase heart rate or contractility — making reflex bradycardia the dominant heart rate effect rather than the competing direct beta-1 chronotropic stimulation seen with norepinephrine

3. Clonidine is a non-catecholamine adrenergic agonist with a mechanism of action and clinical profile that differs fundamentally from phenylephrine despite both being alpha-adrenergic agonists. Which of the following correctly identifies clonidine's primary receptor target, its mechanism of action, and its principal clinical use?

• A) Clonidine is a selective alpha-2 adrenergic agonist that acts primarily at central alpha-2 receptors in the brainstem (locus coeruleus, nucleus tractus solitarius, and rostral ventrolateral medulla); central alpha-2 activation reduces sympathetic outflow to the heart and vasculature, lowering heart rate, blood pressure, and peripheral vascular resistance; it also activates presynaptic alpha-2 autoreceptors on peripheral sympathetic terminals, further reducing norepinephrine release; principal clinical uses include hypertension, procedural sedation and anxiolysis, opioid and nicotine withdrawal management, ADHD (attention deficit hyperactivity disorder), and as an adjunct in pain management
• B) Clonidine is a selective alpha-1 adrenergic agonist that acts peripherally on vascular smooth muscle to produce vasoconstriction; it raises blood pressure and is used as a vasopressor in hypotensive emergencies; it is classified alongside phenylephrine and midodrine as a peripheral alpha-1 agonist vasopressor
• C) Clonidine is a non-selective beta adrenergic agonist that increases heart rate and cardiac contractility through beta-1 activation while producing bronchodilation through beta-2 activation; its antihypertensive effect results from the reduction in cardiac output that paradoxically follows the initial tachycardia through baroreceptor-mediated compensatory bradycardia
• D) Clonidine is a selective alpha-2 agonist that acts exclusively at peripheral presynaptic autoreceptors on sympathetic nerve terminals, reducing norepinephrine release into the synaptic cleft; it has no central nervous system activity because it does not cross the blood-brain barrier; its antihypertensive mechanism is purely peripheral NE reduction without any central sympatholysis
• E) Clonidine is a selective imidazoline receptor agonist with no adrenergic receptor activity; its antihypertensive effect results entirely from activation of I1 imidazoline receptors in the rostral ventrolateral medulla, which reduce sympathetic drive independently of alpha-2 receptor stimulation; the alpha-2 receptor classification of clonidine is a historical pharmacological error now corrected in current literature

4. Albuterol (salbutamol) is the most widely prescribed beta-2 adrenergic agonist and a first-line bronchodilator in asthma and COPD. Which of the following correctly identifies albuterol's receptor selectivity, its mechanism of bronchodilation, and why it is preferred over epinephrine for routine asthma management?

• A) Albuterol is a non-selective beta agonist with equal activity at beta-1 and beta-2 receptors; it produces bronchodilation through beta-2 activation and simultaneously increases heart rate and contractility through beta-1 activation; it is preferred over epinephrine because its non-selectivity provides more complete sympathetic stimulation and faster onset of bronchodilation
• B) Albuterol is a selective alpha-1 antagonist that blocks bronchoconstrictor alpha-1 receptors on airway smooth muscle; by blocking alpha-1 receptor-mediated bronchoconstriction, it allows the airway to relax; it is preferred over epinephrine because it does not activate any adrenergic receptors and therefore has no cardiovascular side effects
• C) Albuterol is a selective beta-2 adrenergic agonist that produces bronchodilation through Gs/cAMP/PKA-mediated phosphorylation and inactivation of myosin light chain kinase (MLCK) in airway smooth muscle; its beta-2 selectivity means it produces less beta-1-mediated cardiac stimulation (tachycardia, increased contractility) than epinephrine; it is preferred over epinephrine for routine asthma management because its relative beta-2 selectivity provides effective bronchodilation with a more favorable cardiac safety profile
• D) Albuterol is a selective beta-2 adrenergic agonist that produces bronchodilation through Gs/cAMP/PKA-mediated MLCK inactivation in airway smooth muscle, causing relaxation; compared to epinephrine, albuterol's beta-2 selectivity produces effective bronchodilation with reduced beta-1-mediated cardiac side effects (tachycardia, arrhythmia risk); additionally, as a non-catecholamine, albuterol is not inactivated by COMT — allowing inhalational delivery with sustained local airway effect (4–6 hours), oral formulation, and absence of rapid systemic degradation; epinephrine remains appropriate for anaphylaxis where its simultaneous alpha-1 and beta-1 activity is essential, but is not the agent of choice for isolated bronchospasm in routine asthma
• E) Albuterol is a selective beta-2 agonist that differs from epinephrine only in its route of administration — both have identical receptor profiles and produce identical bronchodilation; albuterol is preferred over epinephrine because it can be inhaled while epinephrine cannot; the inhaled route provides local airway delivery without systemic absorption, explaining albuterol's safety advantage

5. Midodrine is an orally administered non-catecholamine alpha-1 agonist used in the management of orthostatic hypotension (OH) — a condition in which blood pressure drops significantly upon standing due to inadequate peripheral vasoconstriction. Which of the following correctly explains why midodrine is effective in orthostatic hypotension and identifies its key pharmacological properties?

• A) Midodrine is effective in orthostatic hypotension because it activates beta-1 receptors in the heart, increasing cardiac output and heart rate upon standing; the increased cardiac output compensates for the failure of peripheral vasoconstriction; midodrine is preferred because it is orally bioavailable and has no alpha-adrenergic activity, avoiding the supine hypertension that alpha agonists cause
• B) Midodrine is a prodrug converted to its active metabolite desglymidodrine (an alpha-1 selective agonist) after oral absorption; desglymidodrine produces peripheral alpha-1-mediated vasoconstriction, increasing vascular tone and venous return in the upright position — directly compensating for the peripheral vasomotor failure that causes orthostatic hypotension; key properties: oral bioavailability (prodrug strategy avoids first-pass inactivation), selective alpha-1 activity (no significant beta effects, no CNS penetration), and short-to-moderate duration of action; supine hypertension is a recognized adverse effect requiring patients to avoid lying down within 4 hours of dosing
• C) Midodrine is effective because it is a centrally acting alpha-2 agonist (like clonidine) that increases central sympathetic tone by activating excitatory alpha-2 receptors in the brainstem; increased sympathetic outflow raises peripheral vascular resistance in the upright position; midodrine is preferred over clonidine for orthostatic hypotension because it produces excitatory rather than inhibitory central effects
• D) Midodrine works by inhibiting norepinephrine reuptake at sympathetic nerve terminals (similar to cocaine and tricyclic antidepressants), increasing synaptic NE concentrations and activating peripheral adrenergic receptors; it is classified as an indirect-acting sympathomimetic rather than a direct-acting agonist; its oral bioavailability makes it practical for outpatient management of orthostatic hypotension
• E) Midodrine is a direct-acting alpha-1 agonist given orally that increases peripheral vascular resistance to treat orthostatic hypotension; unlike desglymidodrine, midodrine itself is the active compound; it crosses the blood-brain barrier and produces significant central sedation as a recognized side effect that limits its use in cognitively impaired elderly patients

6. A student compares phenylephrine and clonidine and notes: "Both are alpha adrenergic agonists — yet one raises blood pressure and the other lowers it. How can two drugs acting on the same receptor family produce opposite effects on blood pressure?" Which of the following best resolves this apparent paradox?

• A) The paradox is resolved by dose — at low doses both phenylephrine and clonidine raise blood pressure through alpha-1 activation; at high doses both lower blood pressure through alpha-2 activation; the clinical difference between the two drugs is purely a matter of dose selection, not receptor subtype selectivity
• B) The paradox does not exist — both phenylephrine and clonidine raise blood pressure; clonidine is incorrectly classified as an antihypertensive because its initial dose produces a transient blood pressure rise through peripheral alpha-1 activation before the central alpha-2 antihypertensive effect takes over; the net effect of both drugs over time is blood pressure elevation
• C) The paradox is resolved by receptor subtype and anatomical location — phenylephrine selectively activates postsynaptic alpha-1 receptors on peripheral vascular smooth muscle, directly producing vasoconstriction and raising blood pressure; clonidine selectively activates alpha-2 receptors, predominantly at presynaptic nerve terminals and in brainstem vasomotor centers, reducing sympathetic outflow and thereby reducing peripheral vascular resistance and blood pressure; the same receptor family (adrenergic) contains subtypes that, when activated in different locations by selective agonists, produce diametrically opposite cardiovascular outcomes
• D) The paradox is resolved by signal transduction — phenylephrine activates Gq-coupled alpha-1 receptors raising intracellular calcium and producing vasoconstriction; clonidine activates Gs-coupled alpha-2 receptors raising cAMP and producing vasodilation; it is the G protein coupling that determines the direction of the blood pressure effect, not the anatomical location of the receptor
• E) The paradox is resolved by noting that clonidine is not truly an antihypertensive — it lowers blood pressure only acutely through sedation-related reduction in cardiac output; at steady state, clonidine has no blood pressure-lowering effect and its chronic antihypertensive use is not supported by evidence; phenylephrine's sustained alpha-1 vasoconstriction produces durable blood pressure elevation

7. A 58-year-old man with hypertension has been taking clonidine 0.2 mg twice daily for 6 months. He abruptly discontinues the medication without tapering after running out of his prescription over a long weekend. On day 2 without clonidine, he presents to the emergency department with severe headache, blood pressure 198/112 mmHg, heart rate 108 bpm, and diaphoresis. Using non-catecholamine pharmacology, which of the following best explains the mechanism of this clinical presentation?

• A) Abrupt clonidine discontinuation causes rebound hypotension because clonidine's alpha-1 vasopressor effect is suddenly lost; the 198/112 mmHg reading is a measurement artifact caused by the patient's anxiety about running out of medication rather than a true pharmacological withdrawal effect
• B) Abrupt clonidine discontinuation produces rebound hypertension because chronic clonidine therapy downregulates alpha-2 receptors in the brainstem; when clonidine is stopped, the downregulated receptors are no longer able to respond to endogenous NE, permanently impairing central sympathetic regulation; this permanent receptor downregulation explains the permanent nature of clonidine withdrawal hypertension
• C) Abrupt clonidine discontinuation produces a withdrawal syndrome characterized by rebound hypertension, tachycardia, and sympathetic hyperactivity; the mechanism is: chronic clonidine suppresses central sympathetic outflow, causing compensatory upregulation of postsynaptic alpha-1 receptors and increased sensitivity of the peripheral sympathetic system; when clonidine is abruptly withdrawn, the suppression is suddenly removed, and the now-sensitized sympathetic system produces a rebound surge in NE release and sympathetic activity that overshoots baseline, producing hypertensive crisis; this is analogous to beta blocker withdrawal producing rebound tachycardia through similar receptor upregulation mechanisms
• D) Abrupt clonidine discontinuation causes rebound hypertension because clonidine inhibits MAO during chronic therapy; when clonidine is stopped, MAO inhibition is suddenly reversed, causing rapid NE degradation that paradoxically produces excessive NE release as a compensatory response; the mechanism is therefore MAO disinhibition rather than central receptor upregulation
• E) Abrupt clonidine discontinuation has no pharmacological withdrawal syndrome; the blood pressure elevation in this patient reflects progression of his underlying hypertension during the period without medication rather than a drug-specific withdrawal effect; clonidine does not produce receptor adaptations during chronic use and therefore cannot produce rebound phenomena

8. Beta-2 selective agonists such as albuterol and terbutaline are preferred over non-selective beta agonists such as isoproterenol for bronchodilation in asthma. A student asks: "If both activate beta-2 receptors and produce bronchodilation, what clinically important difference justifies the preference for selective agents?" Which of the following best answers this question?

• A) Beta-2 selective agonists (albuterol, terbutaline) produce bronchodilation through beta-2 receptor activation while producing significantly less beta-1-mediated cardiac stimulation (tachycardia, increased contractility, arrhythmia risk) compared to non-selective beta agonists (isoproterenol) — which activate beta-1 and beta-2 receptors with equal potency; in patients with underlying cardiac disease, asthma exacerbations are already physiologically stressful; adding significant beta-1-mediated tachycardia and arrhythmia risk from a non-selective agent compounds the cardiac stress; selective agents provide the required bronchodilation without the clinically unnecessary and potentially harmful cardiac stimulation; this selectivity advantage was the primary driver for developing beta-2 selective agonists as isoproterenol replacements in the 1970s
• B) Beta-2 selective agonists produce bronchodilation through a different signal transduction pathway than non-selective agonists — selective agonists use the Gs/cAMP pathway while non-selective agonists use the Gq/IP3 pathway; the Gs pathway produces more sustained bronchodilation with less tachyphylaxis (receptor desensitization) than the Gq pathway, which accounts for the clinical preference for selective agents
• C) Beta-2 selective agonists are preferred because they produce bronchodilation without any cardiovascular effects whatsoever; beta-2 receptors are exclusively expressed in bronchial smooth muscle and have no expression in cardiac tissue; non-selective beta agonists produce cardiac effects because they activate beta-1 receptors that are exclusively cardiac; the receptor expression patterns are mutually exclusive between airway and heart
• D) Beta-2 selective agonists are preferred because they produce bronchodilation through a direct anti-inflammatory mechanism — selective beta-2 activation reduces mast cell degranulation and prevents histamine release, addressing the underlying inflammatory cause of asthma; non-selective beta agonists do not have this anti-inflammatory effect and only address bronchospasm symptomatically
• E) Non-selective beta agonists such as isoproterenol are actually preferred over selective agents in severe acute asthma because their beta-1 cardiac stimulation maintains cardiac output during the physiological stress of a severe exacerbation; selective beta-2 agonists are only used in mild-to-moderate asthma where cardiac support is not required

9. A patient with severe asthma is treated with inhaled albuterol multiple times per day for several weeks. The treating physician notes that the patient's response to albuterol appears diminished compared to when treatment was initiated. Using beta-2 receptor pharmacology, which of the following best explains this phenomenon?

• A) Prolonged albuterol exposure has permanently destroyed beta-2 receptors in bronchial smooth muscle through receptor downregulation; the lost receptors cannot be replaced and the patient requires permanent dose escalation to achieve any bronchodilation; this represents an irreversible tachyphylaxis unique to beta-2 agonists
• B) The diminished response reflects pharmacokinetic tolerance — prolonged albuterol use induces CYP3A4 in the liver, increasing the rate of albuterol metabolism; higher oral doses are required to achieve the same plasma concentration; this explains why inhaled albuterol becomes less effective with prolonged use
• C) The diminished response reflects development of new alpha-1-mediated bronchoconstriction from compensatory upregulation of alpha-1 receptors in bronchial smooth muscle; these upregulated alpha-1 receptors counteract the beta-2-mediated bronchodilation, reducing net airway caliber change; adding an alpha-1 blocker would restore albuterol efficacy
• D) Prolonged beta-2 receptor stimulation triggers GRK (G protein-coupled receptor kinase)-mediated phosphorylation of the beta-2 receptor, promoting beta-arrestin recruitment and receptor internalization (downregulation); the resulting reduction in surface beta-2 receptor density reduces the bronchodilatory response to subsequent albuterol doses — a phenomenon called tachyphylaxis or homologous desensitization; this is a recognized mechanism limiting the efficacy of long-term short-acting beta-2 agonist monotherapy and is part of the rationale for adding inhaled corticosteroids (which upregulate beta-2 receptor expression) in persistent asthma
• E) The diminished response is caused by the patient developing antibodies to albuterol after prolonged exposure; immunological tolerance to inhaled beta-2 agonists is a well-recognized phenomenon that develops within 4–6 weeks of continuous use; switching to a structurally unrelated beta-2 agonist (such as terbutaline) restores full bronchodilatory response

10. A 72-year-old woman with chronic orthostatic hypotension secondary to diabetic autonomic neuropathy (DAN — dysfunction of the autonomic nervous system caused by diabetes, impairing the normal vasoconstrictor response to standing) is started on midodrine. Three days later she calls her physician complaining that her blood pressure at night is dangerously high — 168/96 mmHg when lying down. She takes her last midodrine dose at 6 PM and goes to bed at 10 PM. Which of the following best explains this adverse effect and identifies the appropriate management strategy?

• A) The supine hypertension is caused by midodrine's beta-1 cardiac stimulation in the lying-down position — when the patient lies flat, beta-1-mediated increases in heart rate and contractility produce hypertension that was masked by the orthostatic stress during the day; stopping midodrine and switching to a pure vasodilator would resolve the nocturnal hypertension
• B) Midodrine's active metabolite desglymidodrine produces persistent alpha-1-mediated vasoconstriction regardless of body position; in the upright position this vasoconstriction usefully counteracts orthostatic hypotension; in the supine position the same vasoconstriction raises blood pressure without the gravitational offloading that standing provided; the management strategy is to instruct the patient to take her last dose at least 4 hours before lying down, avoid taking midodrine within 4 hours of bedtime, and sleep with the head of the bed elevated 10–30 degrees to maintain a partial gravitational gradient and reduce the hypertensive effect of the vasoconstriction
• C) The supine hypertension reflects midodrine's central alpha-2 agonist effect — in the upright position the central sympatholytic effect is overridden by gravitational stress; in the supine position the central sympatholysis produces unopposed bradycardia and compensatory hypertension; the management is to add a beta blocker to counteract the compensatory hypertension without interfering with midodrine's orthostatic benefit
• D) Supine hypertension is not a recognized adverse effect of midodrine; the blood pressure readings of 168/96 mmHg reflect white coat hypertension from anxiety about the new medication; no management change is required and the patient should be reassured
• E) The supine hypertension is caused by midodrine-induced renal sodium retention through alpha-1 receptor activation in the renal collecting duct; prolonged alpha-1 stimulation in the kidney expands intravascular volume; the expanded volume causes hypertension when the patient lies down; treatment is a low-sodium diet without changing the midodrine dose or timing

11. A 45-year-old woman with moderate persistent asthma is well-controlled on inhaled budesonide (an inhaled corticosteroid) plus formoterol (a long-acting beta-2 agonist, LABA). She develops a urinary tract infection and her primary care physician prescribes a 5-day course of a non-selective beta blocker (propranolol) for a concurrent episode of supraventricular tachycardia (SVT). Within 12 hours of starting propranolol she experiences significant worsening of her asthma. Using non-catecholamine pharmacology, which of the following best explains why this drug interaction causes bronchospasm, and what a safer alternative would be?

• A) Propranolol blocks beta-2 receptors on bronchial smooth muscle, removing the bronchodilatory tone maintained by endogenous epinephrine and formoterol through the Gs/cAMP/MLCK-inactivation pathway; in an asthmatic patient whose airways are already hyperreactive, removal of beta-2-mediated bronchodilation allows unopposed muscarinic M3-mediated bronchoconstriction to predominate — precipitating bronchospasm; propranolol also competitively blocks the exogenous LABA formoterol at beta-2 receptors, eliminating its therapeutic effect; a safer alternative for SVT in this patient would be a cardioselective (beta-1 selective) beta blocker such as metoprolol or atenolol, which at therapeutic doses has significantly less beta-2 blockade, preserving formoterol's bronchodilatory effect and the patient's airway protection; alternatively, non-beta blocker antiarrhythmics (diltiazem, verapamil) could be used
• B) The interaction occurs because propranolol inhibits CYP2D6, which is responsible for formoterol metabolism; CYP2D6 inhibition raises formoterol plasma concentrations to toxic levels, paradoxically producing beta-2 receptor desensitization and bronchospasm through receptor downregulation; the safer alternative is a beta blocker that does not inhibit CYP2D6
• C) The bronchospasm is caused by propranolol's direct muscarinic M3 agonist activity — propranolol has off-target anticholinergic properties that at high doses switch to muscarinic agonism, directly contracting bronchial smooth muscle; this is unrelated to its beta receptor blocking properties
• D) The interaction occurs because formoterol requires ongoing beta-2 receptor stimulation to maintain its anti-inflammatory effects in the airway — propranolol's beta-2 blockade removes the anti-inflammatory protection, allowing inflammatory mediator release that triggers bronchospasm; the mechanism is immunological rather than pharmacodynamic; no beta blocker is safe in asthmatic patients under any circumstances
• E) Propranolol's bronchospasm risk in this patient is entirely due to its alpha-1 agonist side effect — propranolol has partial alpha-1 agonist activity that causes direct bronchial smooth muscle constriction at therapeutic doses; this is why cardioselective beta blockers (which also have partial alpha-1 agonist activity) are equally contraindicated in asthma

12. Having completed Module 3, a student reflects on the non-catecholamine adrenergic agonists as a class: "What is the unifying pharmacological principle that connects phenylephrine, clonidine, albuterol, and midodrine — four drugs with completely different clinical uses?" Which of the following best captures this unifying principle?

• A) The unifying principle is structural — all four drugs share the catechol ring as their core pharmacophore, explaining their adrenergic receptor binding; their different clinical uses reflect different doses rather than different receptor selectivities
• B) The unifying principle is metabolic — all four drugs are prodrugs that require conversion to an active metabolite for pharmacological activity; the different clinical profiles reflect different active metabolite receptor selectivities rather than differences in the parent drugs themselves
• C) The unifying principle is that all four are non-catecholamines — they lack the catechol ring, conferring resistance to COMT and longer duration of action than catecholamines — but each has a distinct receptor selectivity profile that determines its clinical application: phenylephrine selects alpha-1 (vasopressor, decongestant); clonidine selects alpha-2 (central sympatholytic, antihypertensive); albuterol selects beta-2 (bronchodilator); midodrine (via desglymidodrine) selects alpha-1 in the periphery (orthostatic hypotension); the non-catecholamine structural feature provides the pharmacokinetic platform (oral bioavailability, duration) while receptor selectivity determines the therapeutic application
• D) The unifying principle is clinical — all four drugs are used exclusively in chronic disease management and none has any role in acute or emergency settings; non-catecholamines are defined by their long duration making them unsuitable for acute titration
• E) The unifying principle is that all four drugs produce cardiovascular effects through the same final common pathway — increased intracellular calcium in vascular smooth muscle cells — regardless of the receptor subtype activated; the different clinical applications reflect different vascular beds targeted rather than different cellular mechanisms